Typical cases receiving TVR-based triple therapy with HCV RNA undetectable by CAP/CTM and detectable by ART.

<p>These 3 patients were receiving TVR-based triple therapy and achieved SVR24. (a) Case 1 received TVR-based triple therapy for 12 weeks, and then the patient was treated without TVR up to week 24. HCV RNA was detected by ART only at week 8. *The CAP/CTM result was obtained at week 3. (b) Case 2 received TVR-based triple therapy for 5 weeks, and then the patient was treated without TVR up to week 24. HCV RNA was detected by ART only at week 4. (c) Case 3 received TVR-based triple therapy for 10 weeks, and HCV RNA was detected by ART only at weeks 4 and 8. y.o., year old.—, HCV RNA was undetected. NT, not tested.</p

Dilutions of the WHO HCV RNA Standard that were assayed by CAP/CTM and ART.

<p>Positivity rates of the assays of replicate samples at each concentration are shown. N. S., not significant by the Fisher exact test.</p

Amplification products produced by CAP/CTM and ART.

<p>Each lane from left to right shows the following: molecular weight marker (100-bp ladder), CAP/CTM amplification product, and ART amplification product.</p

Typical results of <i>in vitro</i> cell transfection assay and detection of HCV RNA by CAP/CTM and ART.

<p>These experiments were performed twice, and the mean values of the 2 experiments are shown in Fig 5A and 5B. At day 13, ART detected HCV RNA below the reported lower limit of detection. (A) Results of cell cultures containing TVR 10 μM. (B) Results of cell cultures containing TVR 10 μM plus IFN 100 IU/mL. Bar graph, HCV Ag. Solid lines, CAP/CTM results. Dashed lines, ART results. n. d., not detected. Light-colored characters and lines show the lower limits of detection.</p

The points of disappearance and reappearance of HCV RNA by the CAP/CTM and ART assays of serum specimens from patients receiving TVR-based triple therapy, who were identified with relapse or VBT.

<p>Solid lines, CAP/CTM and ART obtained the same results. Dotted lines, CAP/CTM and ART obtained different results. N. S., not significant by chi-square test.</p

The PPVs for SVR and NPVs for non-SVR in patients receiving DCV/ASV therapy, based on the results of CAP/CTM and ART assays for detecting HCV RNA in samples taken at weeks 4 and 8.

<p>The PPVs for SVR and NPVs for non-SVR in patients receiving DCV/ASV therapy, based on the results of CAP/CTM and ART assays for detecting HCV RNA in samples taken at weeks 4 and 8.</p